Status:
WITHDRAWN
Cardiac Sarcoidosis Response To Steroids Trial
Lead Sponsor:
Ottawa Heart Institute Research Corporation
Conditions:
Cardiac Sarcoidosis
Sarcoidosis
Eligibility:
All Genders
18+ years
Phase:
PHASE4
Brief Summary
There are no published clinical consensus guidelines on the treatment of cardiac sarcoidosis. Corticosteroid therapy is advocated by some experts, but is based on small observational studies, with var...
Eligibility Criteria
Inclusion
- evidence of clinical cardiac sarcoidosis causing significant conduction system disease (defined as complete right bundle branch block and left axis deviation or left bundle branch block or second or third degree AV block in young patients (\< 60 yrs) AND/OR
- evidence of clinical cardiac sarcoidosis causing non-ischemic dilated cardiomyopathy and sustained ventricular tachycardia AND
- PET or MRI imaging supporting the diagnosis of cardiac sarcoidosis
Exclusion
- unable or unwilling to provide informed consent
- history of noncompliance of medical therapy
- patients with active infection
- patients with active inflammatory disease not related to sarcoidosis
- patients with other known causes of heart block or LV dysfunction
- patients with known active malignancy
- patients wwho are pregnant or lactating
- patients with other indications for steroids
Key Trial Info
Start Date :
April 1 2014
Trial Type :
INTERVENTIONAL
Allocation :
ACTUAL
End Date :
December 1 2016
Estimated Enrollment :
Patients enrolled
Trial Details
Trial ID
NCT01210677
Start Date
April 1 2014
End Date
December 1 2016
Last Update
October 30 2013
Active Locations (1)
Enter a location and click search to find clinical trials sorted by distance.
1
University of Ottawa Heart Institute
Ottawa, Ontario, Canada, K1Y 4W7